A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease

A report from the southern network on adverse reactions (SONAR)

Charles L. Bennett, David M. Spiegel, Iain C. MacDougall, Le Ann Norris, Zaina P. Qureshi, Oliver Sartor, Stephen Y. Lai, Martin S. Tallman, Dennis W. Raisch, Sheila Weiss Smith, Samuel Silver, Alanna S. Murday, James Olen Armitage, David Goldsmith

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin prevent transfusions among chemotherapy-associated anemia patients. Clinical trials, meta-analyses, and guidelines identify mortality, tumor progression, and venous thromboembolism (VTE) risks with ESA administration in this setting. Product labels advise against administering ESAs with potentially curative chemotherapy (United States) or to conduct risk-benefit assessments (Europe/Canada). Since 2007, fewer chemotherapy-associated anemia patients in the United States and Europe receive ESAs. ESAs and the erythropoietin receptor agonist peginesatide prevent transfusions among chronic kidney disease (CKD) patients; clinical trials, guidelines, and meta-analyses demonstrate myocardial infarction, stroke, VTE, or mortality risks with ESAs targeting high hemoglobin levels. U.S. labels recommend administering ESAs or peginesatide at doses sufficient to prevent transfusions among dialysis CKD patients. For dialysis CKD patients, Canadian and European labels recommend targeting hemoglobin levels of 10 to 12 g/dL and 11 to 12 g/dL, respectively, with ESAs. ESA utilization for dialysis CKD patients has decreased in the United States.

Original languageEnglish (US)
Pages (from-to)783-796
Number of pages14
JournalSeminars in Thrombosis and Hemostasis
Volume38
Issue number8
DOIs
StatePublished - Oct 31 2012

Fingerprint

Hematinics
Erythropoietin
Chronic Renal Insufficiency
Safety
Neoplasms
Dialysis
Venous Thromboembolism
Drug Therapy
Meta-Analysis
Anemia
Hemoglobins
Clinical Trials
Guidelines
Erythropoietin Receptors
peginesatide
Mortality
Canada
Stroke
Myocardial Infarction

Keywords

  • darbepoetin
  • epoetin
  • erythropoiesis-stimulating agents
  • peginesatide

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease : A report from the southern network on adverse reactions (SONAR). / Bennett, Charles L.; Spiegel, David M.; MacDougall, Iain C.; Norris, Le Ann; Qureshi, Zaina P.; Sartor, Oliver; Lai, Stephen Y.; Tallman, Martin S.; Raisch, Dennis W.; Smith, Sheila Weiss; Silver, Samuel; Murday, Alanna S.; Armitage, James Olen; Goldsmith, David.

In: Seminars in Thrombosis and Hemostasis, Vol. 38, No. 8, 31.10.2012, p. 783-796.

Research output: Contribution to journalReview article

Bennett, CL, Spiegel, DM, MacDougall, IC, Norris, LA, Qureshi, ZP, Sartor, O, Lai, SY, Tallman, MS, Raisch, DW, Smith, SW, Silver, S, Murday, AS, Armitage, JO & Goldsmith, D 2012, 'A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: A report from the southern network on adverse reactions (SONAR)', Seminars in Thrombosis and Hemostasis, vol. 38, no. 8, pp. 783-796. https://doi.org/10.1055/s-0032-1328884
Bennett, Charles L. ; Spiegel, David M. ; MacDougall, Iain C. ; Norris, Le Ann ; Qureshi, Zaina P. ; Sartor, Oliver ; Lai, Stephen Y. ; Tallman, Martin S. ; Raisch, Dennis W. ; Smith, Sheila Weiss ; Silver, Samuel ; Murday, Alanna S. ; Armitage, James Olen ; Goldsmith, David. / A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease : A report from the southern network on adverse reactions (SONAR). In: Seminars in Thrombosis and Hemostasis. 2012 ; Vol. 38, No. 8. pp. 783-796.
@article{09d1c80a137142b49e9d50739136581e,
title = "A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: A report from the southern network on adverse reactions (SONAR)",
abstract = "The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin prevent transfusions among chemotherapy-associated anemia patients. Clinical trials, meta-analyses, and guidelines identify mortality, tumor progression, and venous thromboembolism (VTE) risks with ESA administration in this setting. Product labels advise against administering ESAs with potentially curative chemotherapy (United States) or to conduct risk-benefit assessments (Europe/Canada). Since 2007, fewer chemotherapy-associated anemia patients in the United States and Europe receive ESAs. ESAs and the erythropoietin receptor agonist peginesatide prevent transfusions among chronic kidney disease (CKD) patients; clinical trials, guidelines, and meta-analyses demonstrate myocardial infarction, stroke, VTE, or mortality risks with ESAs targeting high hemoglobin levels. U.S. labels recommend administering ESAs or peginesatide at doses sufficient to prevent transfusions among dialysis CKD patients. For dialysis CKD patients, Canadian and European labels recommend targeting hemoglobin levels of 10 to 12 g/dL and 11 to 12 g/dL, respectively, with ESAs. ESA utilization for dialysis CKD patients has decreased in the United States.",
keywords = "darbepoetin, epoetin, erythropoiesis-stimulating agents, peginesatide",
author = "Bennett, {Charles L.} and Spiegel, {David M.} and MacDougall, {Iain C.} and Norris, {Le Ann} and Qureshi, {Zaina P.} and Oliver Sartor and Lai, {Stephen Y.} and Tallman, {Martin S.} and Raisch, {Dennis W.} and Smith, {Sheila Weiss} and Samuel Silver and Murday, {Alanna S.} and Armitage, {James Olen} and David Goldsmith",
year = "2012",
month = "10",
day = "31",
doi = "10.1055/s-0032-1328884",
language = "English (US)",
volume = "38",
pages = "783--796",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "8",

}

TY - JOUR

T1 - A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease

T2 - A report from the southern network on adverse reactions (SONAR)

AU - Bennett, Charles L.

AU - Spiegel, David M.

AU - MacDougall, Iain C.

AU - Norris, Le Ann

AU - Qureshi, Zaina P.

AU - Sartor, Oliver

AU - Lai, Stephen Y.

AU - Tallman, Martin S.

AU - Raisch, Dennis W.

AU - Smith, Sheila Weiss

AU - Silver, Samuel

AU - Murday, Alanna S.

AU - Armitage, James Olen

AU - Goldsmith, David

PY - 2012/10/31

Y1 - 2012/10/31

N2 - The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin prevent transfusions among chemotherapy-associated anemia patients. Clinical trials, meta-analyses, and guidelines identify mortality, tumor progression, and venous thromboembolism (VTE) risks with ESA administration in this setting. Product labels advise against administering ESAs with potentially curative chemotherapy (United States) or to conduct risk-benefit assessments (Europe/Canada). Since 2007, fewer chemotherapy-associated anemia patients in the United States and Europe receive ESAs. ESAs and the erythropoietin receptor agonist peginesatide prevent transfusions among chronic kidney disease (CKD) patients; clinical trials, guidelines, and meta-analyses demonstrate myocardial infarction, stroke, VTE, or mortality risks with ESAs targeting high hemoglobin levels. U.S. labels recommend administering ESAs or peginesatide at doses sufficient to prevent transfusions among dialysis CKD patients. For dialysis CKD patients, Canadian and European labels recommend targeting hemoglobin levels of 10 to 12 g/dL and 11 to 12 g/dL, respectively, with ESAs. ESA utilization for dialysis CKD patients has decreased in the United States.

AB - The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin prevent transfusions among chemotherapy-associated anemia patients. Clinical trials, meta-analyses, and guidelines identify mortality, tumor progression, and venous thromboembolism (VTE) risks with ESA administration in this setting. Product labels advise against administering ESAs with potentially curative chemotherapy (United States) or to conduct risk-benefit assessments (Europe/Canada). Since 2007, fewer chemotherapy-associated anemia patients in the United States and Europe receive ESAs. ESAs and the erythropoietin receptor agonist peginesatide prevent transfusions among chronic kidney disease (CKD) patients; clinical trials, guidelines, and meta-analyses demonstrate myocardial infarction, stroke, VTE, or mortality risks with ESAs targeting high hemoglobin levels. U.S. labels recommend administering ESAs or peginesatide at doses sufficient to prevent transfusions among dialysis CKD patients. For dialysis CKD patients, Canadian and European labels recommend targeting hemoglobin levels of 10 to 12 g/dL and 11 to 12 g/dL, respectively, with ESAs. ESA utilization for dialysis CKD patients has decreased in the United States.

KW - darbepoetin

KW - epoetin

KW - erythropoiesis-stimulating agents

KW - peginesatide

UR - http://www.scopus.com/inward/record.url?scp=84868567135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868567135&partnerID=8YFLogxK

U2 - 10.1055/s-0032-1328884

DO - 10.1055/s-0032-1328884

M3 - Review article

VL - 38

SP - 783

EP - 796

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 8

ER -